trending Market Intelligence /marketintelligence/en/news-insights/trending/vpph6sqzifrf94onbptcna2 content esgSubNav
In This List

Aurora Cannabis, CanniMed deal clears final regulatory hurdle

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aurora Cannabis, CanniMed deal clears final regulatory hurdle

The Canadian Competition Bureau cleared Aurora Cannabis Inc.'s C$1.1 billion acquisition of CanniMed Therapeutics Inc., a Canadian producer of medical cannabis.

Aurora Cannabis said it received a no-action letter from the Canadian regulator and the approval represents the final regulatory approval required for the deal.

The company will begin the take-up of CanniMed's shares once the 66.67% minimum tender condition is met. As of Feb. 28, 40% of CanniMed's outstanding shares had been tendered.